Company profile
Home IXICO
IXICO is a premier medical imaging services provider, working with pharma and biotech partners to improve the outcomes of CNS trials.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
RESOLUTIONS | Transaction QURFS0Y4WDdhZGlxemtjeA | Paper/PDF filed
Published 04 Nov 2024 06:36
SH01 | Transaction MzQ0MTIzNDI5NGFkaXF6a2N4
Published 29 Oct 2024 10:05
RP04CS01 | Transaction MzQ0MDQ0ODExMmFkaXF6a2N4 | Paper/PDF filed
Published 29 Oct 2024 07:20
RP04CS01 | Transaction MzQ0MDQ0NzY3MWFkaXF6a2N4 | Paper/PDF filed
Published 29 Oct 2024 07:15
RP04CS01 | Transaction MzQ0MDQ0Njg1MmFkaXF6a2N4 | Paper/PDF filed
Published 29 Oct 2024 07:10
RP04CS01 | Transaction MzQ0MDQ0NTczM2FkaXF6a2N4 | Paper/PDF filed
Published 29 Oct 2024 07:10
RP04CS01 | Transaction MzQ0MDQ0NzEwM2FkaXF6a2N4 | Paper/PDF filed
Published 29 Oct 2024 07:09
RP04CS01 | Transaction MzQ0MDQ0NzI2MWFkaXF6a2N4 | Paper/PDF filed
Published 29 Oct 2024 07:08
SH01 | Transaction MzQzOTM1ODYyMmFkaXF6a2N4
Published 14 Oct 2024 03:05
PSC08 | Transaction MzQzNzk0MDA5M2FkaXF6a2N4
Published 01 Oct 2024 10:24
CS01 | Transaction MzQzNzkzNTgyMGFkaXF6a2N4
Published 01 Oct 2024 10:15
AP01 | Transaction MzQzMjYxOTk2MmFkaXF6a2N4
Published 19 Aug 2024 12:10
TM01 | Transaction MzQzMjYxMjg2OGFkaXF6a2N4
Published 19 Aug 2024 11:16
CS01 | Transaction MzQwMzc5NjkzM2FkaXF6a2N4 | Paper/PDF filed
Published 24 Oct 2024 07:14
CS01 | Transaction MzM2MTkyNDM0NWFkaXF6a2N4 | Paper/PDF filed
Published 24 Oct 2024 07:14
CS01 | Transaction MzMyMzQwNzE5N2FkaXF6a2N4 | Paper/PDF filed
Published 24 Oct 2024 06:57
CS01 | Transaction MzI4NjE0Njc5NWFkaXF6a2N4 | Paper/PDF filed
Published 22 Oct 2024 08:34
CS01 | Transaction MzI1MjIyNjcyN2FkaXF6a2N4 | Paper/PDF filed
Published 24 Oct 2024 07:09
CS01 | Transaction MzIyMzA4OTcxNGFkaXF6a2N4 | Paper/PDF filed
Published 22 Oct 2024 08:39
Company registered at Companies House
IXICO plc develops diagnostic medical imaging technology and develops medical image analytics and clinical trials management software platforms.
Economic impacts IXICO had a significant impact on the pharmaceutical industry where medical imaging is rapidly becoming an important tool in clinical trials to assess the safety and efficacy of new drugs using imaging biomarkers. IXICO's imaging biomarkers provide several benefits to pharmaceutical companies: In concept trials of AD therapies the developed biomarkers allow pharmaceutical companies to power their studies with fewer subjects. The developed imaging biomarkers do provide evidence of efficacy with around 100 subjects per arm (an "arm" in a clinical trial refers to any of the treatment groups in a randomized trial. Most randomized trials have two "arms", e.g. untreated vs. treated groups) over 12 months rather than 400 or so per arm needed for cognitive testing. Based on a conservative cost estimate of $30k per subject enrolled, this provides a significant cost saving for the companies. Similarly, pharmaceutical companies use the developed imaging biomarkers to enrich their clinical trials. In the context of clinical trials, such enrichment allows the identification of a population of patients in whom a drug effect, if present, is more likely to be demonstrable. In AD trials that use the developed biomarkers, an increase in the conversion rate in a prodromal Alzheimer's trial from 40% to 60% saves 30% off the cost of a pair of pivotal trials that used progression free survival as an endpoint, and which might otherwise cost $800m - $1bn. Impacts on public policy and services The imaging biomarkers developed in the underpinning research have had a significant impact on informing the development of new guidelines for the use of Magnetic Resonance Imaging (MRI) and low hippocampal volume in regulatory clinical trials: It now seems likely that to modify the course of Alzheimer's Disease, it is necessary to start the treatment in the pre-dementia (or prodromal) phase. The identification of patients at this stage can only be done confidently with the help of biomarkers: imaging provides a non-invasive alternative to cerebrospinal fluid (CSF) biomarkers for this purpose. The critical importance of imaging biomarkers in AD trials has been recognised by the CAMD consortium by submitting to regulators an application to qualify low hippocampal volume as a biomarker. This submission - approved by EMA and currently under review by the FDA - incorporates key data obtained using the underpinning research described here: the availability of this technology, with the regulatory qualification, is having global impact on the design of future trials of AD medicines in the pre-dementia population. In particular, the EMA Committee for Medicinal Products for Human Use has issued a positive opinion on the use of MRI to measure hippocampal volume as a tool to enrich recruitment into regulated clinical trials in the pre-dementia stages of Alzheimer's disease, in which the EMA directly refers to IXICO's technology. This was the first imaging-based biomarker to be qualified by a regulatory agency. Impacts on healthcare The imaging biomarkers developed in the underpinning research have been so effective in clinical trials that IXICO has recently decided also to develop products for diagnostic use (Brain Health Centre). IXICO's product for diagnostics directly uses the methods described in reference of the underpinning research and has also been CE marked. It is currently undergoing trials involving 200 patients as part of new NHS brain health centres.
